An interventional study of CBSvit HS device and Cryotop SC device in Survival and Embryo Quality, sponsored by Universitair Ziekenhuis Brussel. Completed at 1 site in Belgium. Open to female participants aged 18 Years to 36 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-03.
Sponsored by Universitair Ziekenhuis Brussel · Not applicable, Interventional, and Treatment
The survival rate (and embryo quality) of donor oocytes with two commercially available devices.
Donor sibling oocytes will be vitrified with two commercially available devices. The first device is closed vitrification with closed storage and the second device is open vitrification with closed storage. Oocyte acceptors receive oocytes from both devices. With the increase in cooling rate generated by the open vitrification (second device), we expect to get an increase in survival rate of 10%. Besides this, embryo quality will be assessed with oocytes obtained from both devices.
Universitair Ziekenhuis Brussel is the lead sponsor of 362 studies on the registry; 103 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Half of the oocytes of every donor will be vitrified with the Cryo Bio Systems High Security vitrification (CBSvit HS) device; the standard device in our lab.
Device: CBSvit HS device
Half of the oocytes of every donor will be vitrified with the Cryotop closed system (Cryotop SC).
Device: Cryotop SC device
closed vitrification with closed storage
open vitrification with closed storage
Survival rate
The purpose is to assess the survival rate of donor oocytes with the two vitrification devices.
Time frame: up to 6 days after every warming cycle
Embryo development
The purpose is to analyse the pre-implantation development of donor oocytes vitrified with two different devices.
Time frame: up to 6 days after every warming cycle
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitair Ziekenhuis Brussel